Plain-English translation of NCT07363642 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether people with severe asthma can safely reduce or step down their regular asthma medications after starting treatment with , a new injectable biologic therapy. The study will follow about 400 patients in China for up to 52 weeks to see if the medication works well enough to allow doctors to lower doses of other asthma drugs while keeping their asthma under control.
People with severe asthma often need to take multiple medications at high doses, which can cause side effects and be difficult to manage. This trial is exploring whether this new treatment is effective enough to let patients take fewer or lower doses of their other asthma medications, making treatment simpler and safer.
You likely qualify if…
You likely don't qualify if…
You would receive injections of at a study clinic while continuing your current asthma medications. Over the 52-week period, if your asthma remains well-controlled, your doctor would gradually reduce your other asthma medications — lowering doses or stopping them entirely — while monitoring how you respond. You would have regular clinic visits to complete breathing tests, answer questions about your asthma symptoms, and have your health and medication response checked.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
China